Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT02827708 · Completed

Last updated 2026-05-28

This clinical trial tested whether an oral medication called semaglutide, compared to a placebo, could help lower blood sugar levels in adults with type 2 diabetes who also have moderate kidney problems.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 324 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-09 · est. completion 2018-05

Where 117 sites · Denmark, Finland, Israel, Poland, Russia, Sweden, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02827708 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.

Treatments tested

semaglutide Drug

Oral administration once daily.
placebo Drug

Oral administration once daily.

Main thing measured	Change in HbA1c
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02827708 ↗